AtriCure Names David Francischelli as Vice President of Research and Development Business Wire WEST CHESTER, Ohio -- June 24, 2013 AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, today announced that David Francischelli has joined the company as Vice President of Research and Development, effective August 6, 2013. Mr. Francischelli is an accomplished innovator in the medical device industry with over 23 years of experience. Mr. Francischelli has spent much of his career at Medtronic, Inc. in various research capacities; most recently as Director of Research and Development in the company’s Structural Heart business. In this role, he directed all aspects of research and development for radiofrequency and cryogenic surgical ablation technologies; including novel disposable devices and capital equipment systems, developing new approaches to lesion creation and evaluating areas for new therapy applications. Previously, Mr. Francischelli lead research functions for Medtronic’s Atrial Fibrillation and Cardiac Assist Systems sectors. During his tenure at Medtronic, Mr. Francischelli developed the Cardioblate irrigated ablation system, which has treated over 150,000 patients worldwide. In addition to these accomplishments, Mr. Francischelli has been granted over 50 patents, with an additional 80 more pending. He was recently named as a 2013 Top Inventor by Twin Cities Business. "David is a proven leader with a strong record of business and product innovations spanning over twenty years. His experience with atrial fibrillation and ablation technologies will be invaluable as we strive to lead the industry in the treatment of AFib. We could not ask for a better fit for the role, and are thrilled to have David aboard,” said Mike Carrel, President and Chief Executive Officer of AtriCure. David will report directly to Mike Carrel and be a member of the AtriCure Executive Leadership Team. “I have worked with David Francischelli for over a decade, and I am thrilled he is joining AtriCure. David is an innovative leader and talented engineer in the atrial fibrillation space and will be a great addition to the already strong team at AtriCure,” said Dr. Ralph Damiano, Chief of Cardiac Surgery at Washington University School of Medicine. About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative Atrial Fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of Atrial Fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide.The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact: AtriCure, Inc. Andy Wade, 513-755-4564 Vice President and Chief Financial Officer email@example.com or Investor Relations Contact: Westwicke Partners Lynn Pieper, 415-202-5678 Lynn.firstname.lastname@example.org
AtriCure Names David Francischelli as Vice President of Research and Development
Press spacebar to pause and continue. Press esc to stop.